Ретроградна реканалізація коронарних артерій з хронічною оклюзією

С.М. Фуркало

Література

1. 1. Alhejily WA, et al. Retrograde approach to coronary chronic total occlusion via an occluded saphenous bypass graft: a case report. Clin Case Rep. 2013;1(2):54-58.
   2. Brilakis ES, et al. Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2011;4(8):844-850.
   3. Brilakis ES, et al. Retrograde recanalization of native coronary artery chronic occlusions via acutely occluded vein grafts. Catheter Cardiovasc Interv. 2010;75(1):109-113.
   4. Hsu JT, et al. Impact of calcification length ratio on the intervention for chronic total occlusions. Int J Cardiol. 2011;150(2):135-141.
   5. Joyal D, et al. Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis. Am Heart J. 2010;160(1):179-187.
   6. Michael TT, et al. Role of internal mammary artery bypass grafts in retrograde chronic total occlusion interventions. J Invasive Cardiol. 2012;24(7):359-362.
   7. Rathore S, Katoh O, Matsuo H et al. Retrograde percutaneous recanalization of chronic total occlusion of the coronary arteries: procedural outcomes and predictors of success in contemporary practice. Circ Cardiovasc Interv. 2009;2(2):124-132.
   8. Sianos G, et al. Recanalisation of chronic total coronary occlusions: 2012 consensus document from the EuroCTO club. EuroIntervention. 2012;8(1):139-145.
   9. Surmely JF, Katoh O, Tsuchikane E, et al. Coronary septal collaterals as an access for the retrograde approach in the percutaneous treatment of coronary chronic total occlusions. Catheter Cardiovasc Interv. 2007;69(6):826-832.
   10. Touma G, et al. Chronic total occlusions. Current techniques and future directions. IJC Heart & Vasculature. 2015;7:28-39.

    

Гіпертрофічна кардіоміопатія із середньошлуночковою обструкцією та верхівковою аневризмою

Н.Д. Орищин, Ю.А. Іванів, Ю.Г. Кияк, С.С. Павлик, В.С. Мороз, Д.І. Беш, І.М. Бігун

Література

1. 1. Kyiak SO, Barnett OY, Kovalyshyn VI, Kyiak GYu. Correlation between clinical and cellular cardiology. Lviv, 2012. 160 p. (in Ukr.).
   2. Akutsu Y, Shinozuka A, Huang TY, et al. Hypertrophic cardiomyopathy with apical left ventricular aneurysm. Jpn Circ J. 1998;62:127-131.
   3. Duncan K, Shah A, Chaudhry F, et al. Hypertrophic cardiomyopathy with massive midventricular hypertrophy, midventricular obstruction and an akinetic apical chamber. Anadolu Kardiyol Derg. 2006;6:279-282.
   4. Efthimiadis GK, Pagourelias ED, Parcharidou DG, et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. Circ J. 2013;77:2366-2374.
   5. Gao X-J, Kang L-M, Zhang J, Dou K-F. Mid-ventricular obstructive hypertrophic cardiomyopathy with apical aneurysm and sustained ventricular tachycardia: a case report and literature review. Chin Med J. 2011;124:1754-1757.
   6. Ho CY, López B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010;363(6):552-563.
   7. Holloway CJ, Betts TR, Neubauer S, Myerson SG. Hypertrophic cardiomyopathy complicated by large apical aneurysm and thrombus, presenting as ventricular tachycardia. J Am Coll Cardiol. 2010;56:1961.
   8. Krams R, Kofflard MJ, Duncker DJ, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation. 1998;97:230-233.
   9. Maron M, Finley JJ, Bos JM. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118:1541-1549.
   10. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14:13.
   11. Matsubara K, Nakamura T, Kuribayashi T, et al. Sustained cavity obliteration and apical aneurysm formation in apical hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;42:288-295.
   12. Minami Y, Kajamoto K, Terajima Y, et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011;57:2346-2355.
   13. Park J-S, Cho IH, Shin DG, et al. Hypertrophic cardiomyopathy complicated by left ventricular apical necrosis and aneurysm in a young man: FDG-PET findings. Korean J Intern Med. 2007;22:28-31.
   14. Petersen SE, Jerosch-Herold M, Hudsmith LE. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation. 2007;115:2418-2425.
   15. Sanghvi NK, Tracy CM. Sustained ventricular tachycardia in apical hypertrophic cardiomyopathy, midcavitary obstruction, and apical aneurysm. Pacing Clin Electrophysiol. 2007;30:799-803.
   16. Sato Y, Matsumoto N, Matsuo S, et al. Mid-ventricular obstructive hypertrophic cardiomyopathy associated with an apical aneurysm: evaluation of possible causes of aneurysm formation. Yonsei Med. J. 2007;48:879-882.
   17. Schwartzkopff B, Mundhenke M, Strauer BE. Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. J Am Coll Cardiol. 1998;31:1089-1096.
   18. Tse HF, Ho HH. Sudden cardiac death caused by hypertrophic cardiomyopathy associated with midventricular obstruction and apical aneurysm. Heart. 2003;89:178.
   19. Xiao Y, Wang L, Yang Y, et al. Clinical profile and prognosis of left ventricular apical aneurysm in hypertrophic cardiomyopathy. Am J Med Sciences. 2016;351:101-110.

     

Невідкладна хірургічна коронарна реваскуляризація в пацієнтів з гострим інфарктом міокарда  

Б.М. Тодуров, Г.І. Ковтун, С.O. Шелудько, Л.Г. Біцадзе, O.В. Ревенко, А.О. Шпачук, О.В. Пантазі, О.М. Поступальський

Література

1. 1. Bokeria LA, Alekyan BG, Buziashvili YuI. Stenting of coronary arteries with acute myocardial infarction - the current state of the question. Мoskva, 2006. (in Rus.).
   2. Dolgova IA, Kuzmich IN, Shevchenko VA. Postoperative management of a patient with acute myocardial infarction and recurrent ventricular tachycardia / ventricular fibrillation. Cardiac Surgery and Interventional Cardiology. 2012;2:45-50. (in Rus.).
   3. Alexiou K, Kappert U, Staroske A, et al. Coronary surgery for acute coronary syndrome: which determinants of outcome remain? Clin Research Cardiol. 2008;97:601-608.
   4. Assmann A, Boeken U, Akhyari P, et al. Appropriate timing of coronary artery bypass grafting after acute myocardial infarction. Thorac Cardiovasc Surg. 2012;60:446-451.
   5. Caceres M, Weiman DS. Optimal timing of coronary artery bypass grafting in acute myocardial infarction. Ann Thorac Surg. 2013;95:365-372.
   6. Dunning J, Versteegh M, Fabbri A, et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg. 2008;34:73-92.
   7. Funkat AK, Beckmann A, Lewandowski J, et al. Cardiac surgery in Germany during 2011: a report on behalf of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg. 2012;60:371-382.
   8. Hagl C, Khaladj N, Peters S, et al. Acute treatment of ST-segment-elevation myocardial infarction: is there a role for the cardiac surgeon. Ann Thorac Surg. 2009;88:1786-1792.
   9. Khaladj N, Bobylev D, Peters S, et al. Immediate surgical coronary revascularization in patients presenting with acute myocardial infarction. J Cardiothorac Surg. 2013;8:167-175.
   10. Kohl P, Wijns W, Danchin N, et al. Guidelines on myocardial revascularization. Eur J Cardiothorac Surg. 2010;38(Suppl.):1-52.
   11. Lee DC, Oz MC, Weinberg AD, Ting W. Appropriate timing of surgical intervention after transmural acute myocardial infarction. J Thorac Cardiovasc Surg. 2003;125:115-119.
   12. Mehta RH, Harjai KJ, Boura JA, et al. Short-term outcomes of balloon angioplasty versus stent placement for patients undergoing primary percutaneous coronary intervention: Implications for patients requiring early coronary artery bypass surgery. Am Heart J. 2013;165 (6):1000-1007.
   13. Takano T, Goto H, Hoshino K, et al. Coronary artery bypass grafting for acute myocardial infarction in stent ERA. Ann Thorac Cardiovasc Surg. 2011;17 (3):267-272.
   14. Thielmann M, Neuhäuser M, Marr A, et al. Predictors and outcomes of coronary artery bypass grafting in ST elevation myocardial infarction. Ann Thorac Surg. 2007;84(1):17-24.
   15. Weiss ES, Chang DD, Joyce DL, et al. Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data. J Thorac Cardiovasc Surg. 2008;135(3):503-511.
   16. Zielinska M, Plesiewicz I, Walczak A, et al. The role of elective coronary surgery early after acute myocardial infarction in the era of primary percutaneous coronary intervention. Acta Cardiol. 2007;62:183-188.

     

Клінічні характеристики та якість життя пацієнтів з ішемічною хворобою серця перед реваскуляризацією міокарда

Ю.А. Борхаленко, О.Й. Жарінов, Н.Б. Іванюк, К.О. Міхалєв, О.П. Надорак, О.А. Єпанчінцева, Б.М. Тодуров

Література

1. 1. Myasoyedova NA, Tkhostova EB, Belousov YuB. Assessment of the quality of life for various cardiovascular diseases. Qualitative Clinical Practice. 2002;1:10-14. (in Rus.).
   2. Pogosova NV. Aortocoronary shunting operation: influence on various aspects of quality of life of patients. Cardiology. 1998;1:81-88. (in Rus.).
   3. Pogosova NV, Baichorov IKh, Yufereva YuM, Koltunov IE. Quality of life of patients with cardiovascular diseases: the current state of the problem. Cardiology. 2010;4:66-78. (in Rus.).
   4. Yagensky AV, Höfer S, Sichkaruk ІМ, Oldridge N. Otsіka іnchastі zhіtya u pаtsієntіv zіshemіchnuyu hvoroboyu sercya: the results of the valuation of the Ukrainian food store MacNew Heart Disease Health-related Quality of Life. Ukr Cardiol J. 2013;3:22-28. (in Ukr.).
   5. Abdallah М, Wang K, Magnuson E, et al. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. JAMA. 2013;310:1581-1590.
   6. ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery. Circulation. 2004;110:1168-1176.
   7. Austin BA, Wang Y, Smith GL, et al. Systolic function as a predictor of mortality and quality of life in long-term survivors with heart failure. Clin Cardiol. 2008;31:119-124.
   8. ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46 (4):517-592.
   9. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. New Engl J Med. 2012;367. Р. 2375-2384.
   10. Gupta D, Castagno D, Granger C, et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. J Cardiac Failure. 2012;18:78.
   11. Hoekstra T, Lesman-Leegte I, van Veldhuisen Dirk J, et al. Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail. 2013;15 (1):94-102.
   12. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Amer Coll Cardiology. 2004;43, N 3:317-327.
   13. Jones R, White H, Shaw L, Pietrobon R, et al. STICH (surgical treatment for ischemic heart failure) trial enrollment. J Amer Coll Cardiology. 2010;56:490-498.
   14. Kitzman DW. Heart failure with normal systolic function. In: Rich MW, ed. Clinics in Geriatric Medicine: Heart Failure in the Elderly. Philadelphia, Pa: WB Saunders, 2000:489-511.
   15. Khatibzadeh S, Farzadfar F, Oliver J, et al. Worldwide risk factors for heart failure: a systematic review and pooled analysis. Int J Cardiol. 2013;168 (2):1186-1194.
   16. Krannich JH, Lueger S, Weyers P, Elert O. Health-related quality of life two days before, ten days and one year after coronary artery bypass graft surgery. Thorac Cardiovasc Surg. 2007;55:288-292.
   17. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39.
   18. Lenzen MJ, Scholte Op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the Euro Heart Failure Survey. Eur Heart J. 2004;25:1214-1220.
   19. Lewis EF, Lamas GA, O’Meara E, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9 (1):83-91.
   20. Nalysnyk L, Fahrbach K, Reynolds MW, et al. Adverse events in coronary artery bypass graft (CABG) trials: a systematic review and analysis. Heart. 2003;89 (7):767-772.
   21. Rector TS, Cohn JN. Assessment of Patient Outcome with the Minnesota Living with Heart failure Questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J. 1992;124:1017-1025.
   22. Rumsfeld JS, MacWhinney S, McCarthy M. Health-related quality of life as a predictor of mortality following coronary artery bypass graft surgery. JAMA. 1999;281:1298-1303.
   23. Westin L, Nilstun T, Carlsson R, Erhardt L. Patients with ischemic heart disease: quality of life predicts long-term mortality. Scand Cardiovasc J. 2005;39:50-54.
   24. Yusuf S. Effect of coronary artery bypass graft surgery on survival: overview of 10 year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344 (8934):1446.

    

Хірургічне лікування дефекту міжшлуночкової перегородки,  поєднаного з недостатністю тристулкового клапана

Л. Манюк

Література

1. 1. Bokeria LA, Zelenikin MA, Shatalov KV, et al. Transcuticular access to the defect of the interventricular septum when it is closed. Russian Journal of Thoracic and Cardiovascular Surgery. 2000;5:11-13. (in Rus.).
   2. Kaidash AN. Reconstructive surgery of the tricuspid valve in rheumatic heart diseases. Russian Journal of Thoracic and Cardiovascular Surgery. 1997;6:13-18. (in Rus.).
   3. Skopin II, Sinev AF, Sazonenkov MA, et al. Anatomic and clinical justification of the efficacy of annuloplasty of the tricuspid valve de Vega. Russian Journal of Thoracic and Cardiovascular Surgery. 2001;3:4-7. (in Rus.).
   4. De Vega NC. La anuloplastia selectiva, regulable y permanente. Una tecnica original para el tratamiento de la insuficiencia tricuspide. Rev Esp Cardiol. 1972;25:555-556.
   5. Fukuda S, Gillinov AM, McCarthy PM, et al. Determinants of recurrent or residual functional tricuspid regurgitation after tricuspid annuloplasty. Circulation. 2006;114 (Suppl I):582-587.
   6. Ghanta RK, Chen R, Narayanasamy N, et al. Suture bicuspidization of the tricuspid valve versus ring annuloplasty for repair of functional tricuspid regurgitation: Midterm results of 237 consecutive patients. J Thorac Cardiovasc Surg. 2007;113:117-126.
   7. Goetz WA, Liebold A, Vogt F, et al. Tricuspid valve repair in a case with congenital absence of left thoracic pericardium. Eur J Cardio-thoracic Surgery. 2004;26:848-849.
   8. Hachiro Y, Takagi N, Koyanagi T, Abe T. Reoperation for tricuspid regurgitation after total correction of tetralogy of Fallot. Ann Thorac Cardiovasc Surg. 2002;8:199-203.
   9. Hagler DJ, Squarcia U, Cabalka AK, et al. Mechanism of tricuspid regurgitation in paramembranous defect. J Am Soc Echocardiogr. 2002;15 (4):364-348.
   10. Kanter KR, Doelling NR, Fyfe DA, et al. De Vega tricuspid annuloplasty for tricuspid regurgitation in children. Ann Thorac Surg. 2001;72:1344-1348.
   11. Katogi T, Aeba R, Ito T, et al. Surgical management of isolated congenital tricuspid regurgitation. Ann Thorac Surg. 1998;66:1571-1574.
   12. Maile S, Kadner A, Turina MI, et al. Detachment of the anterior leaflet of the tricuspid valve to expose perimembranous ventricular septal defects. Ann Thorac Surg. 2003;75:944-946.
   13. McCarthy PM, Bhudia SK, Rajeswaran J, et al. Tricuspid valve repair: Durability and risk factors for failure. J Thorac Cardiovasc Surg. 2004;127:674-685.
   14. Mihale C, Lambertz H, Nikol S, et al. Selective annuloplasty of the tricuspid valve. Two-year experience. J Thorac Cardiovasc Surg. 1990;99:846-851.
   15. Minette MS, Sahn DJ. Ventricular septal defects. Circulation. 2006;114:2190-2197.
   16. Monro JL, Alexiou C, Salmon AP, et al. Reoperations and survival after primary repair of congenital heart defects in children. J Thorac Cardiovasc Surg. 2003;126:511-520.
   17. Motoyoshi N, Tokuji M, Sakurai M.et al. Cleft on tricuspid anterior leaflet. Ann Thorac Surg. 2001;71:1350-1351.
   18. Ootaki Y, Yamaguchi M, Yoshimura N, et al. Tricuspid valve repair with papillary muscle shortening for severe tricuspid regurgitation in children. Ann Thorac Surg. 2004;78:1486-1488.
   19. Roos-Hesselink JW, Meijboom FJ, Spitaels SEC, et al. Outcome of patients after surgical closure of ventricular septal defect at young age: longitudinal follow-up of 22-34 years. Eur Heart J. 2004;25:1057-1062.
   20. Sasson L, Katz MG, Ezri T, et al. Indications for tricuspid valve detachment in closure of ventricular septal defect in children. Ann Thorac Surg. 2006;82:958-963.
   21. Sugimoto T, Okada M, Ozaki N, et al. Influence of functional tricuspid regurgitation on right ventricular function. Ann Thorac Surg. 1998;66:2044-2050.
   22. Vettukattil JJ. Is tricuspid valve annuloplasty required in children with right heart obstruction and tricuspid valve regurgitation. Ann Thorac Cardiovasc Surg. 2006;81:405-409.
   23. Wang J, Liang Y, Hayashi J. Selective Annuloplasty for Tricuspid Regurgitation in Children. Ann Thorac Surg. 2005;79:937-941.
   24. Yiwu L, Yingchun C, Jiangun Z, et al. Exact quantitative selective annuloplasty of the tricuspid valve. J Thorac Cardiovasc Surg. 2001;122 (3):611-614.

    

Огляд рекомендацій Європейського товариства кардіологів щодо ведення інфекційного ендокардиту в пацієнтів з імплантованими внутрішньосерцевими пристроями

М.Т. Ватутін, А.М. Шевельок, Є.В. Картамишева, А.О. Тараторіна, К.С. Гасендич, Є.В. Єщенко, Ю.П. Гриценко, О.К. Ставинська

Література

1. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis. The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075-3128.

Шунтування вінцевих артерій

J. Alexander, P. Smith

Література

1. 1. Acar C, Ramsheyi A, Pagny JY, et al. The radial artery for coronary artery bypass grafting: clinical and angiographic results at five years. J Thorac Cardiovasc Surg. 1998;116:981-989.
   2. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol. 2014;63:747-762.
   3. Afilalo J, Eisenberg MJ, Morin JF, et al. Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery. J Am Coll Cardiol. 2010;56:1668-1676.
   4. Afilalo J, Rasti M, Ohayon S.M, et al. Off-pump vs. on-pump coronary artery bypass surgery: an updated meta-analysis and meta-regression of randomized trials. Eur Heart J. 2012;33:1257-1267.
   5. Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294:2446-2454.
   6. Allen K, Cheng D, Cohn W, et al. Endoscopic vascular harvest in coronary artery bypass grafting surgery: a consensus statement of the International Society of Minimally Invasive Cardiothoracic Surgery (ISMICS) 2005. Innovations (Phila). 2005;1:51-60.
   7. Bangalore S, Guo Y, Samadashvili Z, et al. Everolimuseluting stents or bypass surgery for multivessel coronary disease. N Engl J Med. 2015;372:1213-1222.
   8. BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007;49:1600-1606.
   9. Bonow RO, Maurer G, Lee K.L, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617-1625.
   10. Bradley SM, Spertus JA, Kennedy KF, et al. Patient selection for diagnostic coronary angiography and hospital-level percutaneous coronary intervention appropriateness: insights from the National Cardiovascular Data Registry. JAMA. Intern Med. 2014;174:1630-1639.
   11. Brener SJ, Lytle BW, Casserly IP, et al. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation. 2004;109:2290-2295.
   12. Castleberry AW, Williams JB, Daneshmand MA, et al. Surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience. Circulation. 2014;129:2547-2556.
   13. Chan PS, Patel MR, Klein LW, et al. Appropriateness of percutaneous coronary intervention. JAMA. 2011;306:53-61.
   14. Chieffo A, Meliga E, Latib A, et al. Drug-eluting stent for left main coronary artery disease: the DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. JACC. Cardiovasc. Interv. 2012;5:718-727.
   15. Coronary Artery Surgery Study (CASS) Principal Investigators and Their Associates. CASS: a randomized trial of coronary bypass surgery: survival data. Circulation. 1983;68:939-950.
   16. Coylewright M, Shepel K, Leblanc A, et al. Shared decision making in patients with stable coronary artery disease: PCI choice. PLoS One. 2012;7 (11):e49827.
   17. Cummings S.R, Studenski S, Ferrucci L. A diagnosis of dismobility - giving mobility clinical visibility: a Mobility Working Group recommendation. JAMA. 2014;311:2061-2062.
   18. De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991-1001.
   19. Deo SV, Dunlay SM, Shah IK, et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Card Surg. 2013;28:109-116.
   20. Desai ND, Cohen EA, Naylor CD, Fremes S.E. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med. 2004;351:2302-2309.
   21. Diegeler A, Borgermann J, Kappert U, et al. Off-pump versus on-pump coronary- artery bypass grafting in elderly patients. N Engl J Med. 2013;368:1189-1198.
   22. Edwards FH, Clark RE, Schwartz M. Coronary artery bypass grafting: the Society of Thoracic Surgeons National Database experience. Ann Thorac Surg. 1994;57:12-19.
   23. ElBardissi AW, Aranki SF, Sheng S, et al. Trends in isolated coronary artery bypass grafting: an analysis of the Society of Thoracic Surgeons adult cardiac surgery database. J Thorac Cardiovasc Surg. 2012;143:273-281.
   24. Epstein AJ, Polsky D, Yang F, et al. Coronary revascularization trends in the United States, 2001-2008. JAMA. 2011;305:1769-1776.
   25. Farkouh ME, Dangas G, Leon MB, et al. Design of the Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) Trial. Am Heart J. 2008;155:215-223.
   26. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367:2375-2384.
   27. Ferguson TB Jr, Coombs LP, Peterson ED. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA. 2002;287:2221-2227.
   28. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/ SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;64:1929-1949.
   29. Frutkin AD, Lindsey JB, Mehta SK, et al. Drug-eluting stents and the use of percutaneous coronary intervention among patients with class I indications for coronary artery bypass surgery undergoing index revascularization: analysis from the NCDR (National Cardiovascular Data Registry). JACC. Cardiovasc Interv. 2009;2:614-621.
   30. Gao G, Zheng Z, Pi Y, et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol. 2010;56:1639-1643.
   31. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics — 2014 update: a report from the American Heart Association. Circulation. 2014;129 (3):e28-e292.
   32. Goff SL, Mazor KM, Ting HH, et al. How cardiologists present the benefits of percutaneous coronary interventions to patients with stable angina: a qualitative analysis. JAMA. Intern Med. 2014;174:1614-1621.
   33. Hannan EL, Cozzens K, Samadashvili Z, et al. Appropriateness of coronary revascularization for patients without acute coronary syndromes. J Am Coll Cardiol. 2012;59:1870-1876.
   34. Hannan EL, Racz MJ, Gold J, et al. Adherence of catheterization laboratory cardiologists to American College of Cardiology/ American Heart Association guidelines for percutaneous coronary interventions and coronary artery bypass graft surgery: what happens in actual practice? Circulation. 2010;121:267-275.
   35. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med. 2005;352:2174-2183.
   36. Hannan EL, Wu C, Walford G, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med. 2008;358:331-341.
   37. Harskamp RE, Bagai A, Halkos ME, et al. Clinical outcomes after hybrid coronary revascularization versus coronary artery bypass surgery: a meta-analysis of 1,190 patients. Am Heart J. 2014;167:585-592.
   38. Harskamp RE, Brennan JM, Xian Y, et al. Practice patterns and clinical outcomes after hybrid coronary revascularization in the United States: an analysis from the society of thoracic surgeons adult cardiac database. Circulation. 2014;130:872-879.
   39. Head SJ, Kaul S, Mack MJ, et al. The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. Eur Heart J. 2013;34:2510-2518.
   40. Hess CN, Lopes RD, Gibson CM, et al. Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. Circulation. 2014;130:1445-1451.
   41. Hillis LD, Smith P K, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58 (24):e123-210.
   42. Hlatky MA, Bacon C, Boothroyd D, et al. Cognitive function 5 years after randomization to coronary angioplasty or coronary artery bypass graft surgery. Circulation. 1997;96 (Suppl.):II-11-II15.
   43. Hlatky MA, Boothroyd DB, Baker L, et al. Comparative effectiveness of multivessel coronary bypass surgery and multivessel percutaneous coronary intervention: a cohort study. Ann Intern Med. 2013;158:727-734.
   44. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373:1190-1197.
   45. Hlatky MA, Boothroyd DB, Reitz BA, et al. Adoption and effectiveness of internal mammary artery grafting in coronary artery bypass surgery among Medicare beneficiaries. J Am Coll Cardiol. 2014;63:33-39.
   46. Ibrahim K, Tjomsland O, Halvorsen D, et al. Effect of clopidogrel on midterm graft patency following off-pump coronary revascularization surgery. Heart Surg Forum. 2006;9 (6):E581-856.
   47. Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J. 2011;32:2125-2134.
   48. Kappetein AP, Head SJ, Morice MC, et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg. 2013;43:1006-1013.
   49. Kelly R, Buth KJ, Legare JF. Bilateral internal thoracic artery grafting is superior to other forms of multiple arterial grafting in providing survival benefit after coronary bypass surgery. J Thorac Cardiovasc Surg. 2012;144:1408-1415.
   50. Kouchoukos NT, Barzilai B, Davila-Roman VG. Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med. 1997;336:1605-1607.
   51. Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015;131:927-964.
   52. Lamy A, Devereaux PJ, Prabhakaran D, et al. Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med. 2013;368:1179-1188.
   53. Lamy A, Devereaux PJ, Prabhakaran D, et al. Off-pump or on-pump coronaryartery bypass grafting at 30 days. N Engl J Med. 2012;366:1489-1497.
   54. Lopes RD, Mehta RH, Hafley GE, et al. Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. Circulation. 2012;125:749-756.
   55. Malenka DJ, Leavitt BJ, Hearne MJ, et al. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. Circulation. 2005;112 (Suppl.):I-371-I-376.
   56. Mannacio VA, Di Tommaso L Antignan A, et al. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. Heart. 2012;98:1710-1715.
   57. McDonagh DL, Berger M, Mathew JP, et al. Neurological complications of cardiac surgery. Lancet. Neurol. 2014;13:490-502.
   58. Michler RE, Smith PK, Parides MK, et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2016;374:1932-1941.
   59. Mohr F, Redwood S, Venn G, et al. Final five-year follow-up of the SYNTAX trial: optimal revascularization strategy in patients with three-vessel disease. J Am Coll Cardiol. 2012;60 ( Suppl.):B13.
   60. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381:629-638.
   61. Nam CW, Mangiacapra F, Entjes R, et al. Functional SYNTAX score for risk assessment in multivessel coronary artery disease. J Am Coll Cardiol. 2011;58:1211-1218.
   62. Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16:9-13.
   63. National Heart, Lung, and Blood Institute. What to expect after coronary artery bypass grafting (http://www .nhlbi .nih .gov/ health/ health-topics/ topics/cabg/ after.html).
   64. Newman MF, Kirchner JL, Phillips-Bute B, et al. Longitudinal assessment of neurocognitive function after coronaryartery bypass surgery. N Engl J Med. 2001;344:395-402.
   65. Nocerino AG, Achenbach S, Taylor AJ. Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting. Am J Cardiol. 2013;112:1576-1579.
   66. O’Connor GT, Olmstead EM, Nugent WC, et al. Appropriateness of coronary artery bypass graft surgery performed in northern New England. J Am Coll Cardiol. 2008;51:2323-2328.
   67. Ong AT, Serruys PW, Mohr FW, et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J. 2006;151:1194-1204.
   68. Online STS Adult Cardiac Surgery Risk Calculator (http://riskcalc .sts .org/ STSWebRiskCalc).
   69. Online SYNTAX Score calculator (http://www .syntaxscore .com).
   70. Park DW, Kim YH, Song HG, et al. Long-term comparison of drug-eluting stents and coronary artery bypass grafting for multivessel coronary revascularization: 5-year outcomes from the Asan Medical Center-Multivessel Revascularization Registry. J Am Coll Cardiol. 2011;57:128-137.
   71. Park S-J, Ahn J-M, Kim Y-H, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med. 2015;372:1204-1212.
   72. Park S-J, Kim Y-H, Park D-W, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med. 2011;364:1718-1727.
   73. Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/ AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2012;59:857-881.
   74. Pijls NH, Tanaka N, Fearon WF. Functional assessment of coronary stenoses: can we live without it? Eur Heart J. 2013;34:1335-1344.
   75. Proceedings from the National Summit on Overuse. Organized by The Joint Commission and the American Medical Association-Convened Physician Consortium for Performance Improvement (PCPI) September 24, 2012: 23-9 (http://www .jointcommission .org/ assets/ 1/ 6/ National_ Summit_Overuse .pdf).
   76. Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med. 1996;335:1857-1763.
   77. Rothberg MB, Scherer L, Kashef MA, et al. The effect of information presentation on beliefs about the benefits of elective percutaneous coronary intervention. JAMA. Intern Med. 2014;174:1623-1629.
   78. Selnes OA, Gottesman RF, Grega MA, et al. Cognitive and neurologic outcomes after coronary-artery bypass surgery. N Engl J Med. 2012;366:250-257.
   79. Serruys PW, Morice M-C, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-972.
   80. Shroyer AL, Coombs LP, Peterson ED, et al. The Society of Thoracic Surgeons: 30-day operative mortality and morbidity risk models. Ann Thorac Surg. 2003;75:1856-1865.
   81. Shroyer AL, Grover FL, Hattler B, et al. On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med. 2009;361:1827-1837.
   82. Sianos G, Morel M.-A, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1:219-227.
   83. Sipahi I, Akay MH, Dagdelen S, et al. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med. 2014;174:223-230.
   84. Smith PK, Califf RM, Tuttle RH, et al. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann Thorac Surg. 2006;82:1420-1429.
   85. Smith PK, Puskas JD, Ascheim DD, et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2014;371:2178-2188.
   86. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129. (Suppl. 2):S1-45.
   87. STS adult cardiac surgery database: executive summary (http://www .sts .org/ sites/ default/ files/ documents/ 4thHarvest ExecutiveSummary .pdf).
   88. Suma H, Tanabe H, Takahashi A, et al. Twenty years experience with the gastroepiploic artery graft for CABG. Circulation. 2007;116 (Suppl.):I-188-I-191.
   89. Tabata M, Grab JD, Khalpey Z, et al. Prevalence and variability of internal mammary artery graft use in contemporary multivessel coronary artery bypass graft surgery: analysis of the Society of Thoracic Surgeons National Cardiac Database. Circulation. 2009;120:935-940.
   90. Tarakji KG, Brunken R, McCarthy PM, et al. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation. 2006;113:230-237.
   91. The BARI 2D Study GrouP. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-2515.
   92. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study GrouP. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. N Engl J Med. 1984;311:1333-1339.
   93. Tonino PAL, De Bruyne B, Pijls NHJ, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213-224.
   94. Van Belle E, Rioufol G, Pouillot C, et al. Outcome impact of coronary revascularization strategy reclassification with fractional flow reserve at time of diagnostic angiography: insights from a large French multicenter fractional flow reserve registry. Circulation. 2014;129:173-185.
   95. Varnauskas E, European Coronary Surgery Study GrouP. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med. 1988;319:332-337.
   96. Velazquez E.J, Bonow RO. Revascularization in severe left ventricular dysfunction. J Am Coll Cardiol. 2015;65:615-624.
   97. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607-1616.
   98. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374:1511-1520.
   99. Velazquez EJ, Lee KL, O’Connor CM, et al. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg. 2007;134:1540-1547.
   100. Wahrborg P, Booth JE, Clayton T, et al. Neuropsychological outcome after percutaneous coronary intervention or coronary artery bypass grafting: results from the Stent or Surgery (SoS) Trial. Circulation. 2004;110:3411-3417.
   101. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. N Engl J Med. 2012. 366:1467-1476.
   102. Williams JB, Lopes RD, Hafley GE, et al. Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. J Thromb Thrombolysis. 2013;36:384-393.
   103. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563-570.